A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. This is an ...
Evaluating the utility of rule OP-35 to define preventability of ED visits for oncology patients at an academic cancer center. This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results